Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Average Rating of "Moderate Buy" from Analysts

Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) has earned an average rating of "Moderate Buy" from the ten ratings firms that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $37.56.

Several research analysts recently issued reports on the company. JMP Securities cut their target price on Viridian Therapeutics from $42.00 to $38.00 and set a "market outperform" rating on the stock in a research report on Wednesday, May 7th. The Goldman Sachs Group cut their target price on Viridian Therapeutics from $31.00 to $27.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Needham & Company LLC reaffirmed a "buy" rating and set a $36.00 target price on shares of Viridian Therapeutics in a research report on Tuesday, May 20th. Royal Bank Of Canada cut their target price on Viridian Therapeutics from $46.00 to $45.00 and set an "outperform" rating on the stock in a research report on Wednesday, May 7th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $34.00 target price on shares of Viridian Therapeutics in a research report on Wednesday, April 23rd.

Viridian Therapeutics Trading Up 2.3%

Shares of Viridian Therapeutics stock opened at $15.59 on Monday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 19.49 and a current ratio of 19.49. Viridian Therapeutics has a 52 week low of $9.90 and a 52 week high of $27.20. The stock has a 50 day moving average price of $14.07 and a two-hundred day moving average price of $15.50. The stock has a market capitalization of $1.27 billion, a PE ratio of -4.05 and a beta of 0.39.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported ($0.87) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.95) by $0.08. The company had revenue of $0.07 million for the quarter, compared to analysts' expectations of $0.16 million. Viridian Therapeutics had a negative return on equity of 70.61% and a negative net margin of 102,092.39%. The business's revenue was up .0% on a year-over-year basis. As a group, equities analysts anticipate that Viridian Therapeutics will post -4.03 earnings per share for the current fiscal year.

Institutional Trading of Viridian Therapeutics

Hedge funds have recently made changes to their positions in the company. Amalgamated Bank raised its stake in shares of Viridian Therapeutics by 49.7% in the first quarter. Amalgamated Bank now owns 2,531 shares of the company's stock valued at $34,000 after buying an additional 840 shares during the period. Foresite Capital Management VI LLC bought a new stake in shares of Viridian Therapeutics in the fourth quarter valued at $38,000. AlphaQuest LLC raised its stake in shares of Viridian Therapeutics by 119.0% in the fourth quarter. AlphaQuest LLC now owns 2,795 shares of the company's stock valued at $54,000 after buying an additional 1,519 shares during the period. GAMMA Investing LLC raised its stake in shares of Viridian Therapeutics by 3,892.9% in the first quarter. GAMMA Investing LLC now owns 8,425 shares of the company's stock valued at $114,000 after buying an additional 8,214 shares during the period. Finally, Summit Investment Advisors Inc. raised its stake in shares of Viridian Therapeutics by 24.7% in the fourth quarter. Summit Investment Advisors Inc. now owns 7,646 shares of the company's stock valued at $147,000 after buying an additional 1,516 shares during the period.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.